224 related articles for article (PubMed ID: 9717679)
1. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
Usonis V; Bakasenas V; Chitour K; Clemens R
Infection; 1998; 26(4):222-6. PubMed ID: 9717679
[TBL] [Abstract][Full Text] [Related]
2. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
[TBL] [Abstract][Full Text] [Related]
3. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
[TBL] [Abstract][Full Text] [Related]
4. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
[TBL] [Abstract][Full Text] [Related]
6. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
Senterre J
Rev Med Liege; 1999 Feb; 54(2):122-4. PubMed ID: 10221066
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
[TBL] [Abstract][Full Text] [Related]
8. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Wellington K; Goa KL
Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M
Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP; Abu-Elyazeed R; Povey M; Macias Parra M; Diez-Domingo J; Ahonen A; Korhonen T; Tinoco JC; Weiner L; Marshall GS; Silas PE; Sarpong KO; Ramsey KP; Fling JA; Speicher D; Campos M; Munjal I; Peltier C; Vesikari T; Baccarini C; Caplanusi A; Gillard P; Carryn S; Henry O
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):194-201. PubMed ID: 30849175
[TBL] [Abstract][Full Text] [Related]
11. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
Klinge J; Lugauer S; Korn K; Heininger U; Stehr K
Vaccine; 2000 Jul; 18(27):3134-40. PubMed ID: 10856793
[TBL] [Abstract][Full Text] [Related]
13. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
MMR-158 Study Group
Hum Vaccin Immunother; 2019; 15(4):786-799. PubMed ID: 30785357
[TBL] [Abstract][Full Text] [Related]
14. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
15. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
16. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR.
Mitchell LA; Tingle AJ; Décarie D; Lajeunesse C
Can J Public Health; 1998; 89(5):325-8. PubMed ID: 9813922
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
Mufson MA; Diaz C; Leonardi M; Harrison CJ; Grogg S; Carbayo A; Carlo-Torres S; JeanFreau R; Quintero-Del-Rio A; Bautista G; Povey M; Da Costa C; Nicholson O; Innis BL
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):339-48. PubMed ID: 26582873
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
19. Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children.
Lim FS; Han HH; Bock HL
Ann Acad Med Singap; 2007 Dec; 36(12):969-73. PubMed ID: 18185875
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
Reuman PD; Sawyer MH; Kuter BJ; Matthews H
Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
